Oruka Therapeutics hits 61% complete skin clearance in EVERLAST-B

ORKA-001's high dose achieved 61% PASI 100 and 86% PASI 90 at Week 16, with Phase 3 trials planned for the first half

A brightly lit treatment room shows a white recliner with a beige blanket, an IV pole with an infusion pump, and a side table holding a water bottle and magazines, with abstract art and a potted plant in the background.

Oruka Therapeutics has reported positive Week 16 results from EVERLAST-B, its Phase 2b trial of ORKA-001 in moderate-to-severe plaque psoriasis, with the high-dose arm achieving complete skin clearance in 61% of patients. The Menlo Park-based biotech said the data are consistent with those seen in its earlier EVERLAST-A study and support progression to Phase 3.

ORKA-001 is a half-life-extended monoclonal antibody targeting IL-23p19, an interleukin subunit that drives the inflammatory cascade underlying psoriasis. The molecule is engineered to sustain therapeutic drug levels with infrequent dosing, potentially as little as once or twice a year, which Oruka is positioning as a meaningful convenience advantage over existing agents.

Trial results in detail

EVERLAST-B enrolled 187 patients across 36 sites in the United States, Canada, and Europe, randomised equally across three active doses and placebo. In the high-dose group (600 mg at Weeks 0 and 4), 61% of patients achieved PASI 100 at Week 16 compared with 0% in the placebo group, reaching statistical significance (p less than 0.0001). PASI 90 and IGA 0/1 responses both came in at 86% in the same cohort. Dose-dependent efficacy was evident across all active arms.

The safety profile was described as consistent with the established IL-23p19 class. In the high-dose arm, 39% of patients experienced at least one treatment-emergent adverse event, a rate slightly below the 43% observed in the placebo group. No serious treatment-emergent adverse events occurred in the high-dose group, and no injection-site reactions were recorded in any ORKA-001-treated patient. The most common adverse events across all active groups were upper respiratory tract infection and headache.

Joel Gelfand, James J. Leyden Professor of Dermatology and Epidemiology at the University of Pennsylvania and the trial's lead investigator, said the data suggest ORKA-001 is "likely to be the most effective IL-23-targeting biologic to date," adding that the prospect of once or twice-yearly dosing "would be a paradigm shift in moderate-to-severe psoriasis management."

Market context and competitive landscape

The IL-23 inhibitor class already includes several approved agents: risankizumab (AbbVie's Skyrizi), guselkumab (Johnson and Johnson's Tremfya), and tildrakizumab (Sun Pharma's Ilumya). Skyrizi, in particular, has set a high commercial bar, with AbbVie reporting strong growth driven by psoriasis and psoriatic arthritis indications. Oruka's differentiation case rests primarily on dosing interval rather than a novel mechanism; the ability to sustain PASI 100 responses on an annual or biannual regimen would, if confirmed in Phase 3, represent a genuine convenience step-change for patients and prescribers.

The broader dermatology biologics market continues to attract capital and late-stage competition. Several other companies are exploring extended half-life formats or co-formulated biologics in immune-mediated skin diseases, meaning Oruka will need to move swiftly to secure a regulatory and commercial position before the field narrows.

Near-term catalysts for investors include 52-week durability data from EVERLAST-A, expected in December 2026, and 16-week results from the ORCA-SURGE Phase 2 trial of ORKA-002 in psoriasis, due in the first quarter of 2027. Oruka said it intends to begin regulatory discussions on Phase 3 design immediately, with trial initiation targeted for the first half of 2027. The outcome of those regulatory discussions, and the durability data due in December, will be closely watched by the dermatology investment community as the company prepares for a pivotal programme.